The inhibition of the tested compounds on PARP1 enzymatic activity in a cell-free system was measured with enzyme-linked immunosorbent assays (ELISA)45,46,47. Briefly, NAD+ (6 μmol/L) and the activator deoxyoligonucleotide (100 μg/mL) were diluted in 70 μL of reaction buffer and added to each well of a histone-pre-coated 96-well plate, and this was followed by the addition of 10 μL of the compound or a solvent control. The reaction was started by addition of 20 μL of recombinant human PARP1 (10 ng/well) for 1.5 h. After cells were washed with PBST, 100 μL of anti-PARP polyclonal antibody (Trevigen) was added, and the mixture was incubated for another 1.5 h. After washing the cells, the second antibody, goat anti-rabbit IgG horseradish peroxidase, was added, and the mixture incubated for an additional 30 min. Finally, a solution of 0.03% H2O2 and 2 mg/mL OPD in 0.1 mol/L citrate buffer (pH 5.4) was added, and the mixture was incubated for 10 min. The reaction was stopped by the addition of 2 mol/L H2SO4. A490 was measured with a multi-well spectrophotometer (SPECTRA MAX190). The inhibition rate of PARP1 enzymatic activity was calculated as (A490control-A490treated/A490control)×100%. The concentration required to inhibit 50% of PARP1 enzymatic activity (IC50) was determined with the Logit method.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.